---
document_datetime: 2025-10-09 12:39:48
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/adasuve-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: adasuve-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.2388261
conversion_datetime: 2025-12-22 08:15:05.73995
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Adasuve

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                             | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                    |
|----------------------|-------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10113 /202408  | Periodic Safety Update EU Single assessment - loxapine (pre-dispensed inhalation powder)                          | 25/04/2025                          | 01/10/2025                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10113/202408. |
| II/0033              | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 01/09/2022                          | 31/10/2022                                  | SmPC, Annex II, Labelling        |                                                                                                                                            |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            | and PL   |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------------------------------|
| PSUSA/10113 /202108 | Periodic Safety Update EU Single assessment - loxapine (pre-dispensed inhalation powder)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 07/04/2022 | n/a        |          | PRAC Recommendation - maintenance |
| II/0032             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 06/05/2021 | n/a        |          |                                   |
| II/0030             | Submission of the category 3 final report from Drug Utilization study AMDC-204-403 EU (A Multinational Retrospective Medical Record Review to Evaluate Utilization Patterns of Adasuve-Staccato loxapine for inhalation in agitated persons in routine clinical care). In addition, the MAH also submitted the second report with results of the healthcare professional survey on the effectiveness of the additional risk minimisation measures in Annex 7 of the RMP submitted with this variation. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission | 14/06/2019 | n/a        |          |                                   |
| N/0031              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 13/05/2019 | 31/10/2022 | PL       |                                   |
| PSUSA/10113 /201808 | Periodic Safety Update EU Single assessment - loxapine (pre-dispensed inhalation powder)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 14/03/2019 | n/a        |          | PRAC Recommendation - maintenance |
| IB/0029             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 20/02/2019 | n/a        |          |                                   |

<div style=\"page-break-after: always\"></div>

|                     | authorisation, including the RMP - Other variation                                                                                                                                                                                           |            |            |                                  |                                                                                                                                                                                                                                                                       |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0027             | B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF                                                                                                                                  | 22/11/2018 | n/a        |                                  |                                                                                                                                                                                                                                                                       |
| N/0026              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                             | 07/11/2018 | 31/10/2022 | PL                               |                                                                                                                                                                                                                                                                       |
| PSUSA/10113 /201708 | Periodic Safety Update EU Single assessment - loxapine (pre-dispensed inhalation powder)                                                                                                                                                     | 08/03/2018 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                     |
| R/0024              | Renewal of the marketing authorisation.                                                                                                                                                                                                      | 09/11/2017 | 15/01/2018 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Adasuve in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IA/0023             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 24/05/2017 | n/a        |                                  |                                                                                                                                                                                                                                                                       |
| PSUSA/10113 /201608 | Periodic Safety Update EU Single assessment - loxapine (pre-dispensed inhalation powder)                                                                                                                                                     | 09/03/2017 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                     |
| IB/0022             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                | 21/02/2017 | n/a        |                                  |                                                                                                                                                                                                                                                                       |
| N/0021              | Update of the package leaflet with revised contact                                                                                                                                                                                           | 28/11/2016 | 15/01/2018 | PL                               |                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                     | details of the local representatives for Denmark, Finland, Iceland, Norway, Sweden and Cyprus. In addition, the MAH took the opportunity to make minor linguistic amendments in the Danish labelling and in the Czech, Danish, Icelandic, Norwegian and Swedish package leaflets. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)   |            |            |                        |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| PSUSA/10113 /201508 | Periodic Safety Update EU Single assessment - loxapine (pre-dispensed inhalation powder)                                                                                                                                                                                                                                                                                             | 17/03/2016 | n/a        |                        | PRAC Recommendation - maintenance |
| N/0018              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                     | 28/10/2015 | 15/01/2018 | PL                     |                                   |
| PSUSA/10113 /201502 | Periodic Safety Update EU Single assessment - loxapine (pre-dispensed inhalation powder)                                                                                                                                                                                                                                                                                             | 10/09/2015 | n/a        |                        | PRAC Recommendation - maintenance |
| T/0017              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                  | 13/08/2015 | 25/08/2015 | SmPC, Labelling and PL |                                   |
| IB/0016/G           | This was an application for a group of variations. B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                 | 06/07/2015 | 25/08/2015 | SmPC                   |                                   |
| IAIN/0014           | C.I.8.a - Introduction of or changes to a summary of                                                                                                                                                                                                                                                                                                                                 | 02/06/2015 | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

|                     | Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                       |            |            |                        |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IA/0015             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                             | 28/05/2015 | n/a        |                        |                                   |
| PSUSA/10113 /201408 | Periodic Safety Update EU Single assessment - loxapine (pre-dispensed inhalation powder)                                                                                                                                                                                                                                                                                                                                                                         | 12/03/2015 | n/a        |                        | PRAC Recommendation - maintenance |
| IAIN/0012           | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                  | 08/12/2014 | n/a        |                        |                                   |
| II/0010/G           | This was an application for a group of variations. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 23/10/2014 | 25/08/2015 | SmPC, Labelling and PL |                                   |
| II/0009             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                | 25/09/2014 | 25/08/2015 | SmPC                   |                                   |

<div style=\"page-break-after: always\"></div>

| PSUV/0007   | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                          | 11/09/2014   | n/a        |                        | PRAC Recommendation - maintenance   |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------|
| IAIN/0008   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                 | 05/06/2014   | n/a        |                        |                                     |
| IB/0006     | To extend the shelf life of the finished product from 24 to 36 months. The applicant took the opportunity to revise the shelf life specifications of the finished product in order to bring them in line with the stability protocol. B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) | 08/04/2014   | 03/06/2014 | SmPC                   |                                     |
| PSUV/0005   | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                          | 06/03/2014   | n/a        |                        | PRAC Recommendation - maintenance   |
| IAIN/0004   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                 | 16/12/2013   | n/a        |                        |                                     |
| IAIN/0003   | C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV                                                                                                                                                                                                                                                | 28/05/2013   | n/a        |                        |                                     |
| IB/0002/G   | This was an application for a group of variations. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g.                                                                                                                                                                                                                             | 03/05/2013   | 03/06/2014 | SmPC, Labelling and PL |                                     |

<div style=\"page-break-after: always\"></div>

|             | tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                                                                                    |            |     |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IAIN/0001/G | This was an application for a group of variations. C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system | 17/04/2013 | n/a |